KR20120091221A - 프로가스트린에 대한 모노클로날 항체 및 이들의 용도 - Google Patents

프로가스트린에 대한 모노클로날 항체 및 이들의 용도 Download PDF

Info

Publication number
KR20120091221A
KR20120091221A KR1020127012677A KR20127012677A KR20120091221A KR 20120091221 A KR20120091221 A KR 20120091221A KR 1020127012677 A KR1020127012677 A KR 1020127012677A KR 20127012677 A KR20127012677 A KR 20127012677A KR 20120091221 A KR20120091221 A KR 20120091221A
Authority
KR
South Korea
Prior art keywords
hpg
ser
gly
cdr
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127012677A
Other languages
English (en)
Korean (ko)
Inventor
쥴리 팬퀸
로르 부디에
도미니크 쥬베르
프레드릭 올랑드
Original Assignee
바이오레알리테스
썽뜨르 나쇼날르 드 라 르쉐르쉐 씨엉띠삐끄
인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43086711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20120091221(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이오레알리테스, 썽뜨르 나쇼날르 드 라 르쉐르쉐 씨엉띠삐끄, 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) filed Critical 바이오레알리테스
Publication of KR20120091221A publication Critical patent/KR20120091221A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • General Engineering & Computer Science (AREA)
KR1020127012677A 2009-10-16 2010-10-15 프로가스트린에 대한 모노클로날 항체 및 이들의 용도 Ceased KR20120091221A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25262509P 2009-10-16 2009-10-16
US61/252,625 2009-10-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157017085A Division KR101640520B1 (ko) 2009-10-16 2010-10-15 프로가스트린에 대한 모노클로날 항체 및 이들의 용도

Publications (1)

Publication Number Publication Date
KR20120091221A true KR20120091221A (ko) 2012-08-17

Family

ID=43086711

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127012677A Ceased KR20120091221A (ko) 2009-10-16 2010-10-15 프로가스트린에 대한 모노클로날 항체 및 이들의 용도
KR1020157017085A Active KR101640520B1 (ko) 2009-10-16 2010-10-15 프로가스트린에 대한 모노클로날 항체 및 이들의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157017085A Active KR101640520B1 (ko) 2009-10-16 2010-10-15 프로가스트린에 대한 모노클로날 항체 및 이들의 용도

Country Status (42)

Country Link
US (7) US9611320B2 (cg-RX-API-DMAC7.html)
EP (2) EP3421493B1 (cg-RX-API-DMAC7.html)
JP (3) JP5985987B2 (cg-RX-API-DMAC7.html)
KR (2) KR20120091221A (cg-RX-API-DMAC7.html)
CN (2) CN102791735B (cg-RX-API-DMAC7.html)
AP (1) AP2012006262A0 (cg-RX-API-DMAC7.html)
AR (1) AR078659A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010306119A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012008818B1 (cg-RX-API-DMAC7.html)
CA (1) CA2777691C (cg-RX-API-DMAC7.html)
CL (1) CL2012000914A1 (cg-RX-API-DMAC7.html)
CR (1) CR20120184A (cg-RX-API-DMAC7.html)
CU (1) CU24196B1 (cg-RX-API-DMAC7.html)
CY (1) CY1120913T1 (cg-RX-API-DMAC7.html)
DK (1) DK2488551T3 (cg-RX-API-DMAC7.html)
EA (2) EA029271B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011796A (cg-RX-API-DMAC7.html)
ES (2) ES2973217T3 (cg-RX-API-DMAC7.html)
GE (1) GEP201706604B (cg-RX-API-DMAC7.html)
GT (1) GT201200114A (cg-RX-API-DMAC7.html)
HN (1) HN2012000708A (cg-RX-API-DMAC7.html)
HR (1) HRP20181645T1 (cg-RX-API-DMAC7.html)
IL (2) IL219019B (cg-RX-API-DMAC7.html)
IN (1) IN2012DN03348A (cg-RX-API-DMAC7.html)
LT (1) LT2488551T (cg-RX-API-DMAC7.html)
MA (1) MA33747B1 (cg-RX-API-DMAC7.html)
MX (1) MX351635B (cg-RX-API-DMAC7.html)
NI (1) NI201200054A (cg-RX-API-DMAC7.html)
NZ (2) NZ701709A (cg-RX-API-DMAC7.html)
PE (1) PE20121649A1 (cg-RX-API-DMAC7.html)
PH (1) PH12012500711B1 (cg-RX-API-DMAC7.html)
PL (2) PL3421493T3 (cg-RX-API-DMAC7.html)
PT (1) PT2488551T (cg-RX-API-DMAC7.html)
RS (1) RS57966B1 (cg-RX-API-DMAC7.html)
SG (1) SG10201704933PA (cg-RX-API-DMAC7.html)
SI (1) SI2488551T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800628T1 (cg-RX-API-DMAC7.html)
TN (1) TN2012000159A1 (cg-RX-API-DMAC7.html)
TW (1) TWI537002B (cg-RX-API-DMAC7.html)
UA (1) UA106771C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011045080A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202642B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
RS57966B1 (sr) * 2009-10-16 2019-01-31 Progastrine Et Cancers S A R L Monoklonska antitela na progastrin i njihova upotreba
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
WO2011116954A2 (en) * 2010-03-24 2011-09-29 Bioréalités S.A.S. Prophylaxis of colorectal and gastrointestinal cancer
KR101576174B1 (ko) * 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물
US8785603B2 (en) 2011-05-20 2014-07-22 Siemens Healthcare Diagnostics Inc. Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof
EP2715364A1 (en) 2011-06-01 2014-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the risk of developing a colonic neoplasia
JP6450381B2 (ja) * 2013-07-05 2019-01-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション がんを処置するための可溶性mic中和モノクローナル抗体
MX378944B (es) 2014-04-18 2025-03-10 Univ New York State Res Found Anticuerpos de antígeno anti-tf humanizado.
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
WO2016066671A1 (en) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors
WO2017048629A1 (en) * 2015-09-15 2017-03-23 The Scripps Research Institute Antibodies for generating anti-inflammatory macrophage and related uses
CN108780091A (zh) * 2015-12-31 2018-11-09 普莱戈斯瑞恩癌症有限责任公司 用于检测和治疗卵巢癌的组合物和方法
KR102620651B1 (ko) * 2015-12-31 2024-01-04 신케레스 에스.에이 알.엘. 암 발생의 위험도를 평가하기 위한 조성물 및 방법
ES3011729T3 (en) 2015-12-31 2025-04-08 Ecs Progastrin Sa Compositions and methods for detecting and treating gastric cancer
SG11201908998XA (en) * 2017-03-30 2019-10-30 Progastrine Et Cancers S A R L Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
CN110678753B (zh) * 2017-03-30 2023-10-24 普莱戈斯瑞恩癌症有限责任公司 用于治疗肺癌的组合物和方法
DK3720879T3 (da) * 2017-12-05 2022-06-20 Progastrine Et Cancers S A R L Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer
US20200390913A1 (en) 2017-12-08 2020-12-17 Ecs-Biotracker Sàrl Radiolabeled progastrin in cancer diagnosis
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ecs前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
EP3759492A1 (en) * 2018-02-27 2021-01-06 ECS-Progastrin SA Progastrin as a biomarker for immunotherapy
TWI793238B (zh) * 2018-12-27 2023-02-21 偉喬生醫股份有限公司 體外檢測生物樣品之胃源性蛋白的方法及套組
US20220372125A1 (en) * 2019-10-02 2022-11-24 Aslan Pharmaceuticals Pte. Ltd. Antigen Specific Binding Domains and Antibody Molecules
CN112062846A (zh) * 2020-04-27 2020-12-11 杭州博茵生物技术有限公司 一种g-17单克隆抗体及其应用
CN115785273B (zh) * 2021-09-10 2023-10-31 东莞市朋志生物科技有限公司 一种抗胃蛋白酶原i的抗体及其应用
CN115724949B (zh) * 2022-12-12 2026-05-15 郑州伊美诺生物技术有限公司 一种鼠源lgG单克隆抗体及其制备方法、应用
CN116143920A (zh) * 2022-12-30 2023-05-23 南京岚煜生物科技有限公司 胃泌素17的单克隆抗体及其细胞株的制备方法和应用
EP4509528A1 (en) * 2023-08-16 2025-02-19 Barrelman Biosciences LLC Monoclonal antibodies against veterinary progastrin-like molecules and their uses
CN118126177A (zh) * 2023-11-22 2024-06-04 艾维可生物科技有限公司 抗成熟型胃泌素17的单克隆抗体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム インターナショナル,インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP2567974A3 (en) * 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoclonal antibodies to progastrin
PL2040753T3 (pl) * 2006-05-22 2019-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitory progastryny w leczeniu raka okrężnicy
US7854932B2 (en) 2006-12-19 2010-12-21 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
RS57966B1 (sr) * 2009-10-16 2019-01-31 Progastrine Et Cancers S A R L Monoklonska antitela na progastrin i njihova upotreba
WO2011116954A2 (en) * 2010-03-24 2011-09-29 Bioréalités S.A.S. Prophylaxis of colorectal and gastrointestinal cancer
KR101576174B1 (ko) * 2010-07-26 2015-12-09 르 라보레또레 쎄르비에르 간암 요법을 위한 방법 및 조성물

Also Published As

Publication number Publication date
DK2488551T3 (en) 2018-10-08
CL2012000914A1 (es) 2012-09-14
LT2488551T (lt) 2018-10-25
EA201200597A1 (ru) 2012-12-28
EP2488551A2 (en) 2012-08-22
GT201200114A (es) 2014-08-11
PL2488551T3 (pl) 2019-01-31
US11299542B2 (en) 2022-04-12
AR078659A1 (es) 2011-11-23
CN102791735B (zh) 2016-05-18
MX2012004400A (es) 2012-06-27
US20220195035A1 (en) 2022-06-23
MX351635B (es) 2017-10-23
EP2488551B1 (en) 2018-07-25
SMT201800628T1 (it) 2019-01-11
JP2017212992A (ja) 2017-12-07
ES2973217T3 (es) 2024-06-19
JP5985987B2 (ja) 2016-09-06
JP2015145380A (ja) 2015-08-13
ECSP12011796A (es) 2012-06-29
EA029271B1 (ru) 2018-03-30
CR20120184A (es) 2012-08-20
MA33747B1 (fr) 2012-11-01
CU20120060A7 (es) 2013-04-19
US20110117086A1 (en) 2011-05-19
NZ701709A (en) 2016-06-24
HN2012000708A (es) 2015-06-22
UA106771C2 (uk) 2014-10-10
CU24196B1 (es) 2016-09-30
CN104628857A (zh) 2015-05-20
JP2013507138A (ja) 2013-03-04
TWI537002B (zh) 2016-06-11
TN2012000159A1 (en) 2013-12-12
EP3421493B1 (en) 2024-01-17
US20180022802A1 (en) 2018-01-25
TW201119675A (en) 2011-06-16
US20170174761A1 (en) 2017-06-22
US20170306011A1 (en) 2017-10-26
JP6272793B2 (ja) 2018-01-31
IN2012DN03348A (cg-RX-API-DMAC7.html) 2015-10-23
EP3421493A1 (en) 2019-01-02
CN102791735A (zh) 2012-11-21
NI201200054A (es) 2012-08-20
KR101640520B1 (ko) 2016-07-19
ES2690943T3 (es) 2018-11-23
PL3421493T3 (pl) 2024-04-29
ZA201202642B (en) 2013-06-26
IL219019A0 (en) 2012-06-28
NZ599971A (en) 2014-12-24
SI2488551T1 (sl) 2019-01-31
WO2011045080A2 (en) 2011-04-21
US9611320B2 (en) 2017-04-04
AP2012006262A0 (en) 2012-06-30
US10385125B2 (en) 2019-08-20
RS57966B1 (sr) 2019-01-31
SG10201704933PA (en) 2017-07-28
EA201791876A1 (ru) 2018-01-31
PH12012500711B1 (en) 2019-04-24
PE20121649A1 (es) 2012-12-08
IL219019B (en) 2019-05-30
HK1178183A1 (zh) 2013-09-06
CA2777691C (en) 2018-02-27
PT2488551T (pt) 2018-10-31
BR112012008818B1 (pt) 2021-10-19
CA2777691A1 (en) 2011-04-21
US10385124B2 (en) 2019-08-20
IL254004A0 (en) 2017-10-31
GEP201706604B (en) 2017-01-25
US20170306012A1 (en) 2017-10-26
KR20150082672A (ko) 2015-07-15
CY1120913T1 (el) 2019-12-11
WO2011045080A3 (en) 2011-07-07
IL254004B2 (en) 2023-06-01
EP3421493C0 (en) 2024-01-17
US10377821B2 (en) 2019-08-13
US10385126B2 (en) 2019-08-20
US20200002413A1 (en) 2020-01-02
AU2010306119A1 (en) 2012-05-03
BR112012008818A2 (en) 2018-05-22
HRP20181645T1 (hr) 2018-12-14
PH12012500711A1 (en) 2012-11-12

Similar Documents

Publication Publication Date Title
US20220195035A1 (en) Monoclonal antibodies to progastrin and their uses
KR101570404B1 (ko) 결장직장암 및 위창자암의 예방
AU2017202880B2 (en) Monoclonal Antibodies to Progastrin and their uses
HK40002657A (en) Monoclonal antibodies to progastrin and their uses
HK40002657B (en) Monoclonal antibodies to progastrin and their uses
EA041823B1 (ru) Моноклональные антитела к прогастрину и их применение
HK1178183B (en) Monoclonal antibodies to progastrin and their uses

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20120516

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
AMND Amendment
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20130415

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131029

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140526

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131029

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20140526

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20131227

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20130220

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140924

Patent event code: PE09021S01D

AMND Amendment
PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20150527

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20141224

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20140924

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20140825

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20140526

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20131227

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20131029

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20130220

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150626